IONS — IONIS PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 874015 ·
Last close
$44.50
Market Cap
$7.40B
52W High
$86.74
52W Low
$43.01
ADV30
3,737,460
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 246,091,000 243,091,000 -117,482,000 -92,528,000 3,449,969,000 173,381,000 2,958,555,000
Dec 2025 203,330,000 195,373,000 -214,473,000 -229,394,000 3,523,836,000 372,260,000 3,034,747,000
Sep 2025 156,719,000 154,381,000 -160,173,000 -128,606,000 3,033,091,000 338,341,000 2,415,124,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-496,434,000
Investing CF
$232,150,000
Financing CF
$317,358,000
CapEx
$-71,070,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.46
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,838,369,000
Inventory
$50,833,000
Receivables
$58,845,000
ST Investments
$1,704,520,000
EBIT TTM
$-479,546,000
Pretax Income TTM
$-562,001,000
Interest Exp TTM
$82,455,000
Analysts
21

Yahoo Snapshot (yfinance, live)

Total Revenue
$874,092,992
EBITDA
$-579,484,992
Free Cash Flow
$-346,764,640
Enterprise Value
$9,095,519,232
Total Cash
$2,102,353,024
Total Debt
$2,189,019,904
Shares Out
166,184,322
Trailing EPS
$-3.48
Book Value
$2.65
ROE
-105.5%
ROA
-12.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 943,711,000 -381,717,000 -381,387,000 3,523,836,000 3,034,747,000 489,089,000 -268,583,000
Dec 2024 705,138,000 -475,107,000 -453,897,000 3,003,675,000 2,415,324,000 588,351,000 -500,947,000
Dec 2023 787,647,000 -353,730,000 -366,286,000 2,990,072,000 2,603,386,000 386,686,000 -307,513,000
Dec 2022 587,367,000 -410,191,000 -269,722,000 2,533,876,000 1,960,989,000 572,887,000 -274,370,000

TTM Snapshot

Revenues TTM
$569,400,000
NetIncome TTM
$-481,820,000
OpCashFlow TTM
$0
Assets (Latest)
$3,523,836,000
Forward EPS
$-1.11

Max Pain — expiry 2026-10-16

max pain strike: $52.50 · spot: $46.87 · call oi: 14,513 · put oi: 10,962
Expected Move to 2026-10-16: ±$4.15 (8.85%) — implied range $42.72 – $51.02 · ATM straddle on $47.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SYRE Spyre Therapeutics, Inc. $7.56B $85.69 —
PRAX Praxis Precision Medicines, Inc. $7.84B $280.78 —
AMRX Amneal Pharmaceuticals, Inc. $6.89B $19.77 —
ABVX Abivax S.A. $7.95B $91.06 —
ALKS Alkermes plc. $6.85B $40.85 —

News headlines (Yahoo Finance, 1h cache)

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
2026-09-23 16:13 · Yahoo
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
2026-09-22 12:00 · Yahoo
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-22 11:10 · Yahoo
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
2026-09-20 13:50 · Yahoo
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
2026-09-19 09:02 · Yahoo
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
2026-09-24 16:42 · Yahoo
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
2026-09-23 05:00 · Yahoo
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
2026-09-16 20:03 · Yahoo
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-28 13:57 · Yahoo
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide
2026-09-25 00:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.